Preconditioning with sublethal ischemia attenuates the detrimental effects of subsequent prolonged ischemic in sults. This research elucidates potential in vivo cross-tolerance between different neuronal death-generating treatments such as kainate administration, which induces seizures and global isch emia. This study also investigates the effects of a mild epileptic insult on neuronal death in rat hippocampus after a subsequent, lethal epileptic stress using kainic acid (KA) as a model of epilepsy. Three preconditioning groups were as follows: group I was injected with 5 mg/kg KA before a 6-minute global ischemia; group 2 received a 3-minute global ischemia before 7.5 mg/kg KA; and group 3 was injected with a 5-mg/kg dose of KA before a 7.5-mg/kg KA injection. The interval between treatments was 3 days. Neuronal degeneration, revealed by the
ance to stroke (focal ischemia) are demonstrated by the observation that brief episodes of global ischemia sig nificantly attenuate infarct size in animals subsequently treated with permanent middle cerebral artery occlusion (Simon et al., 1993) . In addition, tolerance to focal isch emia induced by prior exposure to transient focal isch emia has been described in rats (Chen et al., 1996) . Other cellular stresses, including cortical spreading depression (Kawahara et al., 1994; Matsushima et al., 1996) , oxida tive stress (Ohtsuki et aI., 1992) , hypoxia, or hyperther mia also induce protection against ischemic neuronal damage. Similar to ischemic tolerance, hippocampal kin dling or bicuculline-induced seizures also have been shown to increase the resistance of the brain to the neu ronal injury associated with a second epileptic challenge. This has been termed epileptic tolerance (Kelly and McIntyre, 1994; Sasahira et aI., 1995) .
The molecular and cellular processes underlying neu ronal degeneration remain poorly understood. However, neuropathologic states such as ischemia and epilepsy have been shown to share histologic, biological, and metabolic correlates. Several studies demonstrate exten sive neuronal degeneration in selective cellular layers of the hippocampus in both conditions (Lothman and Col lins, 198 1; Pulsinelli et aI., 1982; Smith et aI., 1984; Sperk et aI., 1983) . Global ischemia and kainic acid (KA) (at doses producing epileptic seizures) also greatly en hance neuronal activity and induce sustained depolariza tion and extensive intracellular Ca 2 + entry, which poten tiate the release and action of endogenous excitatory amino acids, activation of caspases, and nitric oxide pro duction, leading to excitotoxic cell death by necrosis, apoptosis, or both (Choi, 1988; Huang et aI., 1994; Namura et aI., 1998; Siesjo and Wieloch, 1985) .
In light of these shared biochemical and histopatho logic features, the first objective of the current study was to characterize the potential existence of in vivo cross tolerance between an excitotoxic KA treatment and glob al ischemia through assessment of necrotic and apoptotic neuronal death in these animal models. Our study also investigates the effects of a mild epileptic insult on neu ronal death after a subsequent, lethal epileptic stress in rat hippocampus using KA as a model of epilepsy. Glob al forebrain ischemia was produced by four-vessel oc clusion (Pulsinelli and Brierley, 1979) . The glutamate analogue KA ""as administered systemically at doses shown to evoke behavioral seizures known resembling human temporal lobe epilepsy (the most common form of adult human epilepsy) (Lothman and Collins, 198 1; Nadler, 198 1; Pulsinelli and Brierley, 1979) . Using these rat models, we investigated the effect of preconditioning by sublethal ischemia or KA-induced seizures on subse quent neuronal degeneration after a more severe isch emic insult or KA treatment. The hippocampus was se lected for assessment of neuronal damage, since this brain structure is among the most vulnerable to both ischemia-and KA-induced neuronal death. Time dependent changes in necrotic and apoptotic neuronal death were determined using cellular DNA fragmenta tion combined with analysis of neuronal density and sil ver impregnation technique. Although the physiologic mechanisms underlying ischemic tolerance remain un known, it is acknowledged that a minimal time interval is required between stimuli (in the different models) for the protective effects to become manifest. This phenomenon suggests the involvement of a biological cascade. In this context, adenosine agonists and ATP-sensitive K + chan nel (KATP) openers mimic some of the cerebroprotective effects of preconditioning. Furthermore, these effects are reversed by adenosine antagonists and KA TP blockers, suggesting that adenosine release and activation of KA TP channels through adenosine A I receptors may constitute an early step of ischemic cerebral preconditioning (Abele and Miller, 1990; Heurteaux et aI., 1995; Perez-Pinzon et al., 1996) . Thus, the second objective of this study was to assess the possibility that adenosine and KA TP channels participate in the biological cascade of protective events associated with KA-induced epileptic tolerance or cross tolerance between KA-induced epilepsy and global ischemia.
MATERIALS AND METHODS

Animals
Experiments were performed on 375 male Wistar rats weigh ing 250 to 300 g (Charles River Breeding Laboratories, St.
Aubin, France). The animals, maintained on a 12: 12 hour light-dark cycle, were given food and water ad libitum and were acclimated to the animal facility for at least 1 week before drug treatment or surgery.
Preconditioning procedures
The preconditioned animal groups were as follows. Group 1 was administered KA (5 mg/kg intraperitoneally) before 6-minute global ischemia (KA5-J6). Group 2 received a 3-minute global ischemia before KA administration (7.5 mg/kg intraperiloneally) (I3-KA7.5). Group 3 was injected with a KA (5 mg/kg intraperitoneally) before a second challenge with KA (7.5 mg/kg intraperitoneally) (KA5-KA 7.5). The time interval between treatments was 3 days. Rats were killed at 3 and 7 days after the last treatment, respectively. Arterial occlusions of 3 and 6 minutes' duration were chosen for sublethal ischemia and lethal ischemic episode, respectively, based on previously pub lished findings. The doses of 5 and 7.5 mg/kg KA were selected based on optimal neuroprotection obtained from a dose response profile in an earlier pilot study (data not shown). The first epileptic stress was chosen so that it did not induce neu ronal death, and 5 mg/kg appeared to be the optimal concen tration in this model. A concentration higher than 5 mg/kg of KA for this first epilepsia would produce neuronal damage in CAl and CA3 pyramidal layers. The second epilepsia must be severe enough to induce neuronal death by itself. A concentra tion of 7.5 mg/kg of KA is enough to substantially damage hippocampal neurons. However, doses of KA for the second epileptic stress cannot exceed 10 mg/kg. Thus, neuronal pro tection conferred by preconditioning is related to the intensity of the second lethal ischemic or epileptic episode. Saline injected or sham-operated animals treated 3 days before KA 7.5 injection or 6-minute ischemia were used as controls. Behav ioral effects of KA were monitored for 4 consecutive hours after injection, and seizure activity was controlled with admin istration of diazepam (7 mg/kg intravenously) after that moni toring period. The severity of limbic seizures was determined using a modification of the behavioral scale proposed by Zhang et al. (1997) . Briefly, the epileptic convulsion profile of animals was classified according to six distinct stages characterized as follow: stage 1, immobilization, staring, mouth and facial movements; stage 2, wet dog shakes; stage 3, forelimb clonus, head nodding, chewing, and yawning; stage 4, rearing, in creased forelimb clonic jerks, salivation and frothing at the mouth; stage 5, hemorrhagic foaming, rearing and falling; and stage 6, intense agitation, jumping, and circling, often leading to death within 68 hours after KA administration. Stage 0 cor responded to animals showing no abnormal behaviors.
Forebrain ischemia was performed by four-vessel occlusion as previously described (Pulsinelli and Brierley, 1979) . Briefly, rats were deeply anesthetized by inhalation of 2% halothane mixed with 30% oxygen and 70% nitric oxide and their body temperature maintained at 37°C with a heating blanket during and in the hours after surgery. The vertebral arteries were ir reversibly occluded by electrocoagulation, and a small diameter silicon tubing was looped around the carotid arteries to facilitate subsequent occlusion. On the following day, both common carotid arteries were clamped with microvascular clamps for 3 or 6 minutes, depending on the treatment condi tion, in awake and spontaneously ventilating animals. Rats lost their righting reflex within I minute of carotid clamping. Ces sation of electroencephalographic activity was confirmed dur ing ischemic insults.
Drug treatments
All drugs were freshly mixed on the day of experimentation.
Kainic acid (Sigma, St. Quentin, France) was dissolved in NaCI 0.9% solution and injected intraperitoneally (5 or 7.5 mglkg).
(-)Cromakalim (Beecham Pharmaceuticals) was first dissolved in ethanol at a concentration of 10-1 mollL and then diluted in NaCI 0.9% solution to reach final concentration of 2 mmollL (10 nmolJ5 J.LL injected). (-)Cromakalim was administered in tracerebroventricularly 30 minutes before KA (7.5 mglkg) in jection. Glibenclamide (Pfizer) was first dissolved in NaOH 0.1 N at a concentration of 10-1 mol/L and then diluted to final concentration of 4 mmollL in NaCI 0.9% solution (20 nmol/5 JLL injected). Glibenclamide was intracerebroventricularly in jected 30 minutes before the initial ischemia, KA injection (5 mg/kg intraperitoneally), or R-phenylisopropyl-adenosine (R-PIA, Research Biochemicals International) (25 jLg/kg intra venously) injection. The R-PIA, dissolved in ethanol at a con centration of 10-1 mollL and then diluted to tinal concentration of 10-4 mollL in NaCI 0.9% solution, was intravenously (25 jLg/kg) administered immediately preceding KA treatment (7.5 mg/kg intraperitoneally). 8-Cyclopentyl-1 ,3-dipropy Ixanthine (DPCPX, Research Biochemicals International) was dissolved in ethanol at a concentration of 10-1 mollL, then diluted to final concentration of 10-3 mollL in NaCI 0.9% solution and injected (250 jLglkg intraperitoneally) 2 hours before the first ischemia or KA (5 mg/kg) injection. A volume of 0.5 mL/kg and 1 mLlkg were injected for R-PIA and DPCPX, respectively. The pH of the solutions was adjusted to 7. With the exception of (-)cromakalim, which was injected once daily during the ex perimental duration, all drugs used as pretreatments were ad ministered only once. Control experiments were performed with intraperitoneal, intracerebroventricular, or intravenous in jection of NaCl 0.9% under the same procedural conditions as those highlighted for the different drugs. A pilot study revealed no significant differences between control rats injected with saline and those injected with vehicle containing NaOH or ethanol at the concentrations used for dilution of the drugs. The same observations also were obtained from earlier studies using similar vehicles.
Tissue preparation
At the end of the experiment, animals were deeply anesthe tized by inhalation of 2% halothane mixed with 30% oxygen and 70% nitric oxide, and the brains were quickly extracted and fresh frozen in isopentane at -45°C. Sections (12 jLm) were cut on cryostat (Leica) and postfixed by immersion in 4% para formaldehydell0-2 mollL phosphate buffer (PBS) for 30 min utes. Slides then were dehydrated in ethanol baths (50%, 70%, and 100%), air dried, and stored at -700C until use. For each brain studied (n = 6 per time point and treatment), 6 sections were placed on 3-aminopropylethoxysilane-coated slides, and 10 slides (randomly chosen) per rat were used in each stage of analysis. A neuropathologist, blind to the experimental condi-
tions, performed the histologic assessment using light micro scopic study.
Analysis of neuronal density on cresyl violet-stained sections
The neuronal density of the hippocampal CAl and CA3 subfields was determined by the method of Kirino et al. (1986) .
Analysis of neuronal density was performed on coronal sec tions of the dorsal hippocampus stained with cresyl violet and corresponding to brain sections located between 3.14 and 4.16 mm posterior to bregma (Paxinos and Watson, 1986) . The total linear length of the CA I and CA3 sectors was measured using a digitizer. The number of living neurons in the stratum py ramidale within CAl and CA3 subfields was counted using a Leica Aristoplan photomicroscope at a magnification of x400.
Neurons that had shrunken cell bodies with surrounding empty spaces were excluded. The neuronal density of CA I and CA3 sectors (i.e., the number of intact pyramidal cells per I mm linear length of the CAI/CA3 stratum pyramidale observed in each 12-jLm section) was quantified. Thus, a mean value for each hippocampal CA 1 /CA3 substructure was obtained from 20 bilateral measurements on 6 sections per animal, for the 6 animals in each of the experimental groups. In KA-treated rat groups, selected rats for neuronal density assessment in the CAl and CA3 hippocampal layers included three animals reaching stage 4 of convulsion and three animals reaching con vulsion stage 5. The neuronal density for a given animal rep resents the average of both the right and left hippocampal neu ronal cell densities. Neuronal density values are expressed as mean ± standard error of the mean. Data analysis was per formed by two-factor (experimental condition and brain region) analysis of variance followed by Tukey's w test for multiple comparisons. A P value of < 5% was considered statistically significant.
Silver impregnation technique
The silver staining method (Gallyas et aI., 1990b ) was used to visualize degenerating argyrophilic cells. For this procedure, frozen sections were dehydrated by successive immersion for 5 minutes in I-propanol baths (50%, 75%, and 100%). Slides then were esterified at 56°C for 16 hours in I-propanol con taining 4 mL of distilled H20 and 0.8 mL concentrated sulfuric acid per 100 mL. The next day, slides were rehydrated in 50% and 25% I-propanol and washed twice in distilled H20. Slides then were acetylated in two successive lO-minute distilled H20 baths containing 1.5% acetic acid and in the silicotungstate developer for 7 minutes. The developer was prepared 3 minutes before use by mixing one part of stock solution A and one part of stock solution B. Solution A contained 100 g Na 2 C0 3 (an hydrous) in J L of distilled H20, whereas solution B contained 2.0 g AgN03, 20 g tungstosilicic acid, and 3.5 mL of 40% formaldehyde, dissolved in I L of distilled water in the given order. Sections then were quickly dipped in distilled water and dried and coverslips were applied.
DNA nick end labeling of tissue sections
Coronal cryostat sections (12 J.Lm) from rats killed 72 hours after the last treatment were used and processed according to the terminal deoxynucleotidyl transferase-mediated 2'-.
deoxyuridine 5'triphosphate-biotin nick-end labeling (TUNEL) method (Gavrieli et aI., 1992) . Briefly, sections were rehy drated in ethanol (95%, 70%, and 50%) followed by PBS and bathed in 0.3% H202 in methanol to inactivate endogenous peroxidase. Sections then were permeabilized in 0.3% Tween/ PBS and washed twice in PBS before application of the TUNEL reaction mixture (Boehringer-Mannheim, Meylan, France). Positive control was obtained by preincubation of a section with DNase I (20 mg/mL) for 15 minutes at 3TC before incubation with biotinylated dUTP. In negative control slides, DNA polymerase was omitted from the incubation with biotinylated dUTP. All slides were incubated in a humid cham ber at 37°C for 2 hours. Sections then were washed twice in PBS and incubated overnight at 4°C with the secondary anti tluorescein-peroxidase conjugate. On the following day, sec tions were washed three times with PBS and labeling revealed with 3' -diaminobenzidine and nickel chloride (DAB-Ni). After a final rinse in distilled H20, coverslips were applied to thc sections.
Analysis of DNA fragmentation
Genomic DNA was extracted from control, ischemic, epi leptic, or preconditioned hippocampi (isolated 3 days after isch emia). Fifty to 100 mg of tissue was lysed in I mL of TRlzol reagent (GlBCO BRL, Pontuise). After addition of 0.2 mL of chloroform, the samples were centrifuged at 12000 x g for 15 minutes at 4°C. After precipitation in ethanol and a series of washes, the DNA was solubilized in 8 mmollL NaOH. Residual RNA was removed by incubation with RNAse A (10 mg/mL) Behavioral responses associated with the different models of tolerance. After systemic KA administration, rats exhibited progressive and dose-dependent stereo typed behavioral seizures. This KA-induced epileptic be havioral profile was monitored for 4 hours after injection using the six distinct stages in the scale described by Zhang et al. (1997) (see Materials and Methods). To enable direct comparisons of the different treatment ef fects, only KA-injected rats displaying comparable sei zure activity and duration were included for the histo pathologic study. Thus, animals that had reached con vulsion stages 4 or S (except for passive controls) were selected to better control for reduced neuronal death not specifically attributable to reduced convulsions but rather resulting from the treatments per se. Table I (part 1) highlights recorded behavioral profiles for the differ ent controls and tolerance models. No abnormal behavior was observed in passive control groups (saline-injected and sham-operated rats). In contrast, most animals of the active control groups, KAS (S mg/kg) and KA7.S (7.S mg/kg), reached stages 4 and S with most rats displaying grade 4 seizures after a systemic KAS injection, whereas an equal proportion of KA 7.S-injected rats reached grade 4 or S seizure levels. Seizure progression was initially characterized by staring spells and wet dog shakes oc curring within the first 30 minutes after KA injection, followed by overt signs of motor limbic seizures lasting approximately 90 minutes and differing in intensity and duration in a dose-dependent manner. Preconditioning with KAS appeared to be associated with slight attenu ation of seizure activity induced by KA7.S (P = 0.04). Thus, a greater proportion of KAS-preconditioned rats KA 5* 4 3 10 2 Saline/3 days/KA 7.5*t 1 I 6 6 3 KA 5/3 days/KA 7.5"1" 3 3 9 3 I 3 min-ischemial3 days/KA 7.5 2 2 4 8 Part 2
Glib + KA 5 2 9 10 3 DPCPX + KA 5 3 9 II 1 Glib + KA 5/3 days/KA 7.5 § 2 8 8 5 DPCPX + KA 5/3 days/KA 7.5 6 9 3 2 Glib + 3 min-ischemial3 days/KA 7.5 4 <) 6 2 DPCPX + 3 min-ischemial3 days/KA 7.5 7 10 3 3 R-PIA + KA 7.5* 6 10 9 3 Crom + KA 7.5* 6 II 9 3 Table I represents the number of animals per treatment conditions reaching the different stages of seizure activity. Epileptic status was assessed using Zhang et al.'s (1997) scale of seizure activity described in the Materials and Methods section. Animal reaching a given behavioral epileptic protile (or stage) also exhibited comparable mean duration of seizure activity. KA 5 and KA 7.5 correspond to administration of KA at doses of 5 and 7.5 mglkg, respectively. Differences were considered statistically significant when P < 0.05 (Tukey's test). Crom. Cromakalin; DPCPX, 8-cyclopentyl-l, 3-dipropylxanthine; Glib, glibenclamide; KA, kainic acid; R-PIA, R-phenylisopropyladenosine.
" Significantly different from saline-injected or sham-operated animals. t Significantly different from KA 7.5 injected animals. ::: Significantly different from KA 5 injected animals. § Significantly different from KA 5/3 days/KA 7.5 injected animals.
reached only stage 4 seizures (instead of stage 5) on administration of KA 7.5 3 days later ( Table I , part I). In contrast, ischemic preconditioning failed to alter the se verity of subsequently induced KA7.5 seizures (P = 0.53). In this model, the development and progression of limbic convulsions appeared comparable in terms of magnitude as that induced by a 7.5-mg/kg dose of KA alone.
Histopathologic changes at the hippocampus. Ne crotic neuronal death was assessed by the silver impreg nation technique, a method found reliable to visualize morphologically damaged neurons (Gallyas et aI., 1990a) , and by analysis of neuronal cell density in CAl and CA3 subfields on cresyl violet-stained sections. Fig  ure I highlights representative argyrophilic stainings ob served in the hippocampal pyramidal cell layers 7 days after the last treatment for the different experimental conditions. Table 2 (part 1) summarizes the scores of To enable direct comparisons between controls (KA5 and KA 7.5) and preconditioned rats, results re ported (histologic illustrations and Table 2 ) correspond to rats displaying intense seizure activity reaching stages 4 or 5, which normally induce neuronal death in the brain. Silver staining appeared to significantly overlap with damaged cellular areas observed with cresyl violet staining (data not shown). As expected, control (saline injected and sham-operated) animals exhibited no neu ronal damage and argyrophilic staining (data not shown). In contrast, dense staining was observed after global ischemia (sham/3 days/6-minute ischemia) or single KA treatment (saline/3 days/KA 7.5). Six-minute global fore brain ischemia induced significant neuronal damage in the CAl hippocampal sector. Necrosis and cellular de generation also were apparent in the dentate hilus (CA4) and, to a lesser extent, in the CA3 pyramidal layer Results are expressed as mean ± SEM (n 6) and represent neuronal densities assessed in cresyl violet stained sections per I mm linear length of hippocampal CAl and CA3 pyramidal layers. A mean value for each CAlICA3 substructure was obtained from 20 bilateral measurements on 6 sections per animal (n = 6) in each of the experimental groups. No significant differences were found between saline-injected and sham-operated rats and values of these groups were pooled and termed Controls. KA 5 and KA 7.5 correspond to administration of KA at doses of 5 and 7.5 mg/kg, respectively. Differences were considered statistically significant when P < 0.05 (Tukey's test). Crom, cromakalin; DPCPX, 8-cyclopentyl-l, 3-dipropylxanthine; Glib, glibenc1amide; KA, kainic acid; R-PIA, R-phenylisopropyladenosine.
* Significantly different from saline-injected or sham-operated animals. t Significantly different from KA 7.5 injected animals. :I: Significantly different from ischemic animals (6 min). § Significantly different from KA 5/3 days/KA 7.5 injected animals.
II Significantly different from KA 5/3 days/6 min-Ischemia group.
'][ Significantly different from 3 min-lschemial3 days/KA 7.5 injected animals. # Significantly different from Glib + R-PIA + KA 7.5 group.
( Fig. 1A) . Compared with the sham-operated group, 40% and 80% of CA3 and CA 1 pyramidal cell populations showed signs of neuronal damage in the ischemic group, respectively (Table 2) . Preconditioning with KAS before 6-minute ischemia almost completely inhibited neuronal loss in the CAl pyramidal cell layer and significantly attenuated neuronal damage in both CA3 and CA4 sub structures (Fig. 1 B) . In that preconditioned group, 93% of CA 1 and 73% of CA3 cells were preserved (Table 2) . Systemic administration of KA 7.S induced severe cellu lar neuronal injury in the CAl, CA3, and CA4 pyramidal layers (Fig. 1 C) . Damage sometimes was observed in CA2, although this cellular layer was largely preserved in many animals. In contrast, both KAS (Fig. lO) or ischemic (Fig. IE) preconditioning provided marked hip pocampal neuronal protection against KA 7 .S-induced neuronal loss. The number of argyrophilic bodies was significantly reduced throughout the different hippocam pal layers compared with controls. However, although KA preconditioning seemed able to equally protect all hippocampal layers, ischemic preconditioning appeared to be more efficient at inhibiting KA7.S-induced CAl rather than CA3-neuronal loss. Table 2 shows that sa line13 days/KA7.S-injected rats lost approximately SO% of neurons in both CAl and CA3 sectors, whereas KAS or ischemic preconditioning afforded a 78% protection in CAl substructure and 83% and 61 % neuronal protection in CA3 subfield, respectively.
In situ labeling of DNA fragmentation. The DNA strand breaks in cell nuclei were detected by the TUNEL method (Gavrieli et aI., 1992) in rats killed 72 hours after the last treatment (Fig. 2) . This time point was selected based on results from a pilot study, which included rats killed 1, 3, and 7 days after treatment. No positive DNA nick end-labeled cells were observed in the brains of saline-injected or sham animals (data not shown). After 6-minute global ischemia, TUNEL-positive neurons were observed throughout the CAl pyramidal layer with an increased concentration of labeled cells in the medial portion. Isolated TUNEL-labeled cells also occasionally were observed in the CA3 and CA4 substructures ( Fig.  2A) . After KA7.S treatment, DNA fragmentation was present in many CAl and CA3 neurons (Fig. 2C) , and scattered positive cells also were observed in the dentate hilus. No consistent TUNEL labeling was observed in cells of the CA2 pyramidal layer and dentate gyrus (data not shown). Preconditioning with KAS completely inhib ited DNA fragmentation induced by 6-minute ischemia (Fig. 2B ) or KA7.S (Fig. 20) . Ischemic preconditioning, however, appeared significantly less efficacious in inhib iting KA7.S-induced TUNEL labeling, especially in the CAl pyramidal layer, where a few TUNEL-positive neu- rons were observed (Fig. 2E) . The presence of "ghost" staining of CA3 pyramidal cells also appeared more pro nounced in rats preconditioned with sublethal ischemia and injected 3 days later with KA7.5. Agarose gel elec trophoresis of labeled DNA extracted from brain tissue (Fig. 3) Behavioral responses after the dif f erent treatments. Table 1 (part 2) summarizes representative behavioral changes for the different treatments. The control groups treated with either a single injection of KA TP antagonist glibenclamide (20 nmol/5 f,LL) or A I antagonist DPCPX (250 f,Lg/kg) failed to demonstrate significant behavioral alteration (data not shown). Rats treated with glibencl amide or DPCPX 30 minutes before a single dose of 5 mg/kg KA displayed a behavioral profile that did not significantly differ from that of animals given a single 5-mg/kg dose of KA (P = 0.99 and P = 0.4 1, respec tively). Moreover, glibenclamide also failed to alter the severity of seizures induced by KA7.5 in rats precondi tioned with a sublethal ischemia (P = 0.66). In contrast, glibenclamide appeared to significantly enhance seizure activity induced by KA7.5 in rats preconditioned with a KA5 injection (P = 0.003), whereas DPCPX had no effect on the severity of KA-induced seizure activity in rats preconditioned with a 5-mg/kg dose of KA (P = 0.59) or sublethal ischemia (P = 0.42). In contrast, rats injected with R-PIA (25 f,Lg/kg) or (-)cromakalim (10 nmol/5 mL) before KA treatment (7.5 mg/kg) displayed a significant reduction of seizures intensity compared with animals treated with a single dose of 7.5 mg/kg KA (P = 0.0006).
Histopathologic changes at the hippocampus. Figure 4 shows representative effects of adenosine AI receptor antagonists and agonists on neuronal (necrotic and apop totic) cell death assessed using silver impregnation and TUNEL stainings in the different experimental condi tions. Histologic representations correspond to rats dis playing comparable sustained KA-induced seizure activ ity reaching stages 4 or 5. Table 2 (part 2) summarizes the scores of neuronal damage assessment performed on cresyl violet sections. Pretreatment with glibenclamide or DPCPX failed to potentiate hippocampal neuronal damage induced by a single 5-mg/kg dose of KA (data not shown). However, the deleterious effects of DPCPX (250 f,Lg/kg) injected before KA5 preconditioning (Figs. 4A and 4B) or sublethal 3-minute ischemia (Fig. 4C) were observed in all hippocampal pyramidal cell layers. Numerous argyrophilic neurons appeared in CAl and CA3 substructures of DPCPX-treated rats, whereas TUNEL-positive neurons were observed mainly in the CA I sector. Compared with respective preconditioned groups, 55% to 72% of CAl and 33% to 52% of CA3 pyramidal cells were damaged in animals pretreated with DPCPX injection before the preconditioning stimulus (KA5 treatment or sublethal ischemia, Table 2 ). In con trast, R-PIA (25 f,Lg/kg) KA7.5 induced neuronal degen eration, a finding consistent with its previously reported neuroprotective properties (MacGregor et aI., 1993) . Eighty-five percent of CAl and CA3 cells were pre- served (Table 2) . Similarly, neuronal damage and apop totic nuclei were inhibited in both CAl and CA3 hippo campal sectors of R-PIA-treated animals (Fig. 4D) . When administered alone, R-PIA had no intrinsic effect and did not affect hippocampal neuronal damage (data not shown). Figure S shows the effects of KA TP channels modulators on necrotic and apoptotic cell death. As high lighted, glibenclamide injected before KAS treatment (Figs. SA and SB) or sublethal 3-minute ischemia (Fig.  SC) significantly inhibited the beneficial effects of KAS treatment before KA 7.S or 6-minute ischemia. Intense argyrophilic staining and numerous TUNEL-positive cells were detected in all sectors of the hippocampus after these treatments (Figs. SA through SC). Animals pretreated with glibenclamide before preconditioning stimulus exhibited enhanced neuronal damage in the CAl (42% to 6S%) and in the CA3 (32% to 38%) com pared with respective preconditioned groups (see Table  2 ). Glibenclamide also antagonized the protective effects J Cereb Blood Flow Metab. Vol. 19. No. 12. 1999 Silver staining TUNEL method of R-PIA, as demonstrated by the presence of numerous argyrophilic neurons and intense TUNEL staining in both CA 1 and CA3 sectors after KA 7.S administration in animals injected with glibenclamide before R-PIA (Fig.  SD) . Compared with rats injected with R-PIA before KA 7.S, glibenclamide-pretreated rats exhibited a 66% and 44% loss of hippocampal CAl and CA3 neurons, respectively. Similar to previously reported findings with ischemic models (Heurteaux et aI., 1993; Heurteaux et aI., 1995) , rats pretreated with (-)cromakalim (10 nmol intracerebroventricularly) before KA 7.S and injected once daily during the recovery period afforded a signifi cant protection (7S% and 89% in CAl and CA3, respec tively) against KA-induced hippocampal neurodegenera tion (Fig. SE) .
DISCUSSION
The findings reported in the current study represent the first demonstration of the existence of bidirectional
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Glib. + KA 5/3 days 1 KA 7.5 cross-tolerance between KA treatment (associated with limbic seizures expression) and global ischemia. In ad dition to mutually protective actions of KA epileptic pre conditioning and sublethal global ischemia on hippocam pal neuronal death, our data further characterize epileptic tolerance, using KA as a model of temporal lobe epi lepsy. The beneficial effects of KA or ischemic precon- ditioning on hippocampal damage induced by a subse quent severe global ischemia or a KA 7.5 treatment were demonstrated using analysis of neuronal density on cre syl violet-stained sections combined with silver impreg nation method and DNA fragmentation assessment. Aga rose gel electrophoretic analysis was used to assess the degree of DNA fragmentation in vitro in hippocampal extracts and validated the TUNEL method. The neuro protection observed in the different preconditioning models appeared of comparable magnitude as that ob served after classic ischemic preconditioning. Thus, KAS preconditioning strongly inhibited neuronal degeneration and apoptosis induced by a 6-minute lethal global isch emic episode. Similarly, ischemic preconditioning effi ciently protected CAl and CA3 pyramidal cell layers against KA 7.S-induced neuronal degeneration. Also, KAS preconditioning significantly attenuated hippocam pal degeneration induced by a subsequent lethal KA epi leptic challenge.
Can the protective effects of ischemic or KA precon ditioning be attributable to a decrease in the intensity or duration of seizural activity after KA7.S? Some obser vations suggest that this is unlikely, since ischemic pre conditioning afforded comparable neuronal protection to epileptic preconditioning but failed to alter KA-induced epileptic convulsions (Table I , part 1). Moreover, al though KAS preconditioning did confer a small reduc tion in the severity of convulsions induced 3 days later by KA7.S, analysis of animals showing similar behav ioral symptoms and convulsion intensity is compatible with the notion that protection may be independent of KA-induced behavioral tolerance. Consistent with these findings, Kelly and McIntyre (1994) also demonstrated that hippocampal kindling enhanced the brain's resis tance to subsequent neuronal damage induced by KA treatment, despite the presence of more generalized con vulsions and development of faster severe limbic status in kindled compared with control animals (Kelly and McIntyre, 1994) . Taken together, these findings support the contention that the protection conferred by our pre conditioning treatments, against excitotoxicity induced by KA7.S, is largely mediated by physiologic mecha nisms outside of those mediating behavioral convulsions per se. Animals preconditioned with KAS also appeared to be well protected against hippocampal necrosis and apoptosis, which otherwise would be observed conse quent to a 6-minute global ischemia. This finding further demonstrates that the observed mutual protection is not seizure-dependent, since KAS pretreatment equally pro tects against neuronal death in animals experiencing sei zures (KA 7.S treatment) and ischemic animals without seizures (6-minute ischemia).
The cascade of events that underlie the mutually pro tective actions of epileptic preconditioning and sublethal ischemia and the protective effects of KAS on subse quent neuronal damage by KA7.S treatment remain poorly understood. The pharmacologic approach of the current report suggests the involvement of adenosine, adenosine Al receptors, and KATP channels to the pro tection observed after ischemic and epileptic precondi tioning. Indeed, the beneficial effects of preconditioning treatments (i.e., KAS or a 3-minute ischemia) appeared J Cereb Blood Flow Metab. Vol. 19, No. 12, 1999 to be suppressed by DPCPX, a selective Al receptor antagonist (Lohse et aI., 1987) . Moreover, neuroprotec tive effects of preconditioning procedures also were sig nificantly suppressed by glibenclamide, a potent blocker of KATP channels. Thus, the enhanced resistance against KA 7.S-induced hippocampal injury (associated with in tense-stages 4 and S-seizure activity) demonstrated in rats preconditioned with either a S mgikg dose of KA or a short 3-minute ischemia, appeared to be completely inhibited in animals pretreated with DPCPX or gliben clamide before epileptic or ischemic preconditioning.
How can this neuronal protection, afforded by two drugs with distinct targets-the Al receptor and the KATP channel-be interpreted? Adenosine, a metabolite of adenosine nucleotides, is released during ischemia, after experimental seizures as well as during seizures in epi leptic patients (During and Spencer, 1992; Rudolphi et aI., 1992b; Winn et aI., 1980) . It is therefore conceivable that adenosine be released in the different precondition ing events used in the current study (i.e., after seizures induction by KAS treatment or after a brief 3-minute ischemia). In this context, adenosine also has been shown to indirectly activate KATP channels through the G-protein pathway after binding to Aj receptor. This has not been directly shown in neurons but is well docu mented in cardiac cells (Kirsch et aI., 1990; Kurachi, 1995) . On the other hand, evidence exists demonstrating the ability of Al receptor agonists (e.g., R-PIA) and ac tivators of KATP channels (e.g., (-)cromakalim) to pro tect against the deleterious effects of brain ischemia (Evans et aI., 1987; Heurteaux et aI., 1995; Rudolphi et aI., 1992b; Von Libitz et aI., 1994) . This work also dem onstrates that both of these substances potently conferred protection against the detrimental effects of KA 7.S in animals expressing intense seizure activity. One particu larly intriguing property is the dependence of precondi tioning on time. In cardiac preconditioning, a delayed or "second window of protection" against infarction also is observed 24 to 72 hours after ischemic preconditioning, and it also involves the early activation of adenosine Aj receptor and KATP channels (Baxter et aI., 1994; Baxter and Yellon, 1997; Bernardo et aI., 1999) . Is the ability of both adenosine and KATP channels to regulate vasomotor tone centrally involved in the neuronal protection ob served in this work? The answer to this question prob ably is no, since the vasodilating properties of adenosine have been shown to be associated with A 2 rather than Al receptor activation (Edvinsson et aI., 1993; Nyce, 1999; Rudolphi et aI., 1992a) . On the other hand, glibencl amide recently has been reported to exert minimal effect on CBF in normoglycemic rats (Horinaka et aI., 1997) and to only partially inhibit dilation of cerebral arterioles in response to hypoxia (Taguchi et aI., 1994) .
It seems that the important step in the different pre conditioning events described in this study is accom-plished through activation of neuronal KATP channels by adenosine. However, adenosine, once liberated by pre conditioning treatments, also could activate other trans duction pathways, independent of that related to the KATP channel, and also is beneficial in neuroprotection. Opening other types of K + channels also could have a neuroprotective effect. Particularly good candidates would be the G-protein-gated inward rectifiers, which are abundantly present in most regions of the brain (Lesage et aI., 1995) and which also are activated by adenosine through the Al receptors (Lauritzen et aI., 1997 ; North, 1989) . However, these particular channels are not blocked by glibenc1amide, and their activation cannot be evaluated because they have no potent and specific blockers. Eliminating the beneficial effects of preconditioning by glibenclamide therefore suggests the participation of KATP channels but does not disqualify the activation of other pathways. Furthermore, although indirect activation of KATP channels by adenosine seems to represent an important step in preconditioning induced cascade of events, it cannot be the sole event leading to a neuroprotection that is maximal only 3 days after the initial protective treatment.
Thus, further research is required to identify other bio logical processes involved. Nevertheless, the findings re ported here provide a better understanding of the nature of brain adaptation against neuronal death induced by ischemia or by excitotoxic compounds like KA, which induce epileptic seizures. Research along these lines also might help subsequent development of new therapeutic strategies capable of modifying the outcome of ischemic and epileptic episodes.
